Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically it is used for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. It is administered by injection into a vein. A liposomal formulation known as liposomal daunorubicin also exists. Daunorubicin was approved for medical use in the United States in 1979. It is on the World Health Organization's List of Essential Medicines. It was originally isolated from bacteria of the Streptomyces type.